Pfizer Trading Volume Surges 72.35 to 1.48 Billion Ranking 85th Amid Trump Drug Price Pressure

On July 31, 2025, Pfizer (PFE) closed at $23.27, down 2.18% from the previous trading day, with a trading volume of $1.48 billion—a 72.35% increase compared to the prior session. The stock ranked 85th in volume among U.S. equities. The decline follows heightened regulatory scrutiny as President Trump intensified pressure on pharmaceutical firms to reduce drug prices.

Trump sent letters to 17 pharmaceutical companies, including Pfizer, demanding they align U.S. drug prices with the lowest rates in other developed nations. This move aligns with the administration’s “Most Favored Nation” pricing plan, which requires firms to submit price reductions by September 29. The directive signals a potential shift in pricing power for Big Pharma, with Pfizer’s revenue streams potentially affected by regulatory constraints.

Despite a 8% rise in Eliquis sales to $3.7 billion in Q2 (co-marketed with Bristol-Myers Squibb), the broader market remains wary of patent expirations and competitive pressures. Analysts highlight that Pfizer’s pipeline, including oncology candidates like atirmociclib, may offset near-term revenue declines. However, the company faces a challenging patent cliff, with key drugs like Ibrance and Vyndaqel losing exclusivity in 2027 and 2028.

A backtest of a volume-driven trading strategy showed a 166.71% return from 2022 to 2025 by purchasing top-volume stocks and holding for one day. This outperformed the S&P 500’s 29.18% return, underscoring the role of liquidity in short-term gains. The strategy’s success reflects market dynamics where high-volume stocks, like Pfizer, benefit from momentum-driven flows, though its efficacy depends on evolving market conditions.